Foresee Pharmaceuticals Foresee Pharmaceuticals Announces Dosing of First Patient in Phase 2/3 Clinical Trial of FP-025 for Treatment of COVID-19 Associated ARDS Posted on 2021-03-282021-06-03 by maxproadmin More >>
SyneuRx US FDA Approves SyneuRx’s IND Application for PhaseΠ Clinical Trial for Adult Patients with Treatment-Resistant Depression and Suicidal Symptoms Posted on 2021-03-262021-06-03 by maxproadmin More >>
EirGenix POSITIVE PHASE III CLINICAL RESULTS FOR EIRGENIX’S PROPOSED TRASTUZUMAB BIOSIMILAR Posted on 2021-03-232021-06-03 by maxproadmin More >>
Acepodia Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells Posted on 2021-03-162021-05-27 by maxproadmin More >>
Advaxis Advaxis to Present at the American Association for Cancer Research (AACR) 2021 Annual Meeting Posted on 2021-03-122021-06-03 by maxproadmin More >>
SyneuRx TFDA Approves SyneuRx to Conduct Phasa Πb/Ш Clinical Trials for its Drug Candidates Treating Schizophrenia Posted on 2021-03-082021-06-03 by maxproadmin More >>
Polaris Pharmaceuticals Polaris Phase III interim analysis of lung mesothelioma carcinoma showed a statistically significant overall survival rate of 80% or higher for the highest grade. Posted on 2021-03-042021-03-22 by maxproadmin More >>
Foresee Pharmaceuticals Foresee Pharmaceuticals Enters Exclusive License Agreement with Intas Pharmaceuticals for Commercialization in the United States Posted on 2021-03-042021-03-22 by maxproadmin More >>